On 9 Nov 2026, our scan flagged BEAM as a post-collapse recovery setup scoring 72 out of 98 (Good tier), with a 68% win probability based on our historical pattern database and a 0.48 to 1 risk to reward profile from the published levels. This is a swing trade setup: win probability reflects a multi-day swing hold, not an intraday move. At $26.41, the conservative target is $28.19 with a stop at $22.67. A further breakout above resistance near $29.76 offers a larger move if momentum continues past the initial target.
Expected figures are probability-weighted from our historical pattern database; Trade R:R is measured from the entry, target and stop levels.
Current Setup
BEAM is forming a post-collapse recovery pattern following recent volatility around Phase 1/2 trial updates for BEAM-302 in alpha-1 antitrypsin deficiency (AATD). The stock is currently at $26.41, sitting 30.97% below its 52-week high but 30.55% above its 52-week low. The structure score of 14.06/15 reflects strong pattern formation with key support at $23.16 and resistance at $29.76. Volume is slightly elevated (1.07x average) and breakout quality scores 11.87/13, indicating solid momentum confirmation is building. The bullish flag secondary pattern identified on September 16 (36 days old) reinforces the recovery setup. With a win probability of 67.65% and overall score of 72.33, this represents a meaningful consolidation with reasonable technical merit.
Stock Context
Beam reported Q2 2026 results highlighting the first patient dosed in July for the global pivotal cohort of the BEAM-302 Phase 1/2 trial, aimed at supporting potential accelerated approval. This pivotal advancement arrived after compelling safety and efficacy updates in March 2026, where the company selected 60 mg as the optimal biological dose for pivotal development, with durable and significant reductions in mutant Z-AAT protein. Q3 2026 results reinforced progress with durable increases in functional AAT from BEAM-302 and a potential BLA submission for risto-cel in sickle cell disease by year-end 2026. On November 5, 2026—just four days ago—Jones Trading initiated coverage on BEAM with a Buy rating and $35.00 price target. H.C. Wainwright has reiterated its Buy rating with a $80.00 price target. However, analyst sentiment shows divergence: Guggenheim lowered its target from $55 to $51 on November 5, and notably Wedbush cut its target from $65 to $28 on October 28, then slightly raised it to $30 on November 4, creating conflicting signals around the stock's near-term trajectory.
What to Expect
A successful breakout from this post-collapse recovery would see BEAM clear the resistance level at $29.76, targeting the conservative measure move to $28.19 (a 6.7% gain from current price). The pattern suggests that above $29.76, momentum should carry the stock toward $31–$32 with sustained volume above the 1.85M average. Invalidation occurs decisively below support at $23.16, which would signal the recovery has failed and downside continuation toward $20 is likely. The 67.65% win probability indicates solid odds for measured-move success, though this remains a mid-volatility environment (ATR 6.44%, beta 1.23). Volume ratio of 1.07x is present but not aggressive; a true breakout would ideally see volume spike >1.5x to confirm institutional accumulation.
Risk Factors
Mixed analyst sentiment poses execution risk: Wall Street Zen downgraded to 'strong sell' on October 31 after earlier downgrades from Wedbush (price cut from $65 to $28 on October 28), and Weiss Ratings maintains a 'sell (d-)' rating. BEAM reported a Q3 2026 net loss of $134.4 million, underscoring the cash burn reality of a pre-commercial biotech. The pivotal BEAM-302 cohort initiation in July 2026 means Phase 1/2 trial data extends 12+ months; negative interim readouts or safety signals could crater the pattern. The stock is currently trading only $3.35 above key support ($23.16), leaving limited margin for error if conviction fades. RSI at 52.45 shows neutral momentum—not overbought, but lack of true strength. Beta of 1.23 amplifies sector volatility; given the broader bearish regime score (-0.55), any biotech sector pullback could trigger support test regardless of BEAM-specific catalysts.
We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading. What the terms mean →
Frequently Asked Questions
Is BEAM a good swing trade?
BEAM scored 72 out of 98 on our post-collapse recovery scan, with a 68% historical win probability over a 2-8 trading days hold. Good setup based on our systematic scoring.
What is the entry, target, and stop loss for this setup?
The setup's reference price is $26.41, with a conservative target of $28.19 and a stop loss at $22.67.
What would invalidate this post-collapse recovery setup?
A close below the stop loss at $22.67 would invalidate the setup and suggest the pattern has failed.
How is the win probability calculated?
Win probability is a calibrated estimate of how similar historical post-collapse recovery setups performed over the following 10 trading days, drawn from a database of 370,000+ historical pattern detections across 6,000+ NYSE and NASDAQ stocks.
Market & Sector Regime
Market
Bearish-0.55
-1.00+1.0
Health Care Sector
Bullish0.79
-1.00+1.0
Other Patterns Detected Today
Bull Flag
36 days in pattern
Good
32.0
Overall Score
37of 40
Exceptional
Pattern Quality
14of 20
Good
Setup
11of 20
Fair
R/R
10of 18
Fair
Context
Pattern Quality Score
14of 15
Exceptional
Structure
12of 13
Exceptional
Breakout
11of 12
Exceptional
Volume
Recent Performance
-3.0%
1W
+9.8%
2W
+7.4%
1M
-3.2%
3M
Momentum & Trend
RSI (14)
52.5
Neutral
MACD Histogram
+0.15
Bullish
Bollinger Band Position
64.2%
Mid Zone
Volatility & Risk
20-Day Volatility
0.82
Very High
ATR %
6.4%
High
Beta
1.23
Above Mkt
Volume Analysis
Volume Ratio
1.07x
Average
20-Day Avg Vol
1.8M
shares / day
Current Volume
2.0M
shares traded
Price Levels
52W High
$38.26
Resistance
$29.76
Target
$28.19
Current
$26.41
Support
$23.16
Stop Loss
$22.67
52W Low
$20.23
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.